Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s):  AGNPF

Consumer Cyclical Healthcare Advertising Agencies Biotechnology
Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N... see more

Bullboard (CSE:AGN)

View:
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
Post by Whalewatcher1on Apr 04, 2023 4:20pm

Algernon Neuro - Why would anyone invest in it?

Algernon Neuro has a $20M pre-money valuation and the almost $2M in debt and trying to raise $10M since beginning of year. Meanwhile Algernon Phamra has $2.4M valuation today and would control 75% of ...more  
173
Post by waves1on Apr 04, 2023 3:51pm

AGN doses second cohort in Phase 1 study of DMT!

Algernon Pharmaceuticals (AGN.c AGNPF) has completed the dosing of the second cohort in its escalating dose Phase 1 clinical study of an IV formulation of DMT.   The purpose of this study is ...more  
77
Post by StockHawk1on Apr 03, 2023 6:07pm

AGN to raise money for AGN Neuro subsidiary

Algernon NeuroScience, a wholly owned subsidiary of Algernon Pharmaceuticals (AGN.c AGNPF) has qualified its Form 1-A offering statement filed with the U.S. Securities and Exchange Commission under a ...more  
130
Post by C10H12N2on Apr 02, 2023 10:30pm

AP Loves The Thrill Of The Hunt Way More Than Kill-er Data

I don't see (understand) where anything prevents those eligible for the Rights Offering from buying and dumping existing stock. Canadian shareholders are literally on the verge of determining ...more  
302
Discussion
Post by Whalewatcher1on Mar 31, 2023 9:38pm

Why would anyone purchase their rights offering?

Looking at this rights offering closer, If 100% is subscribed, $2.2M comes in ($2.4M – 0.2M fees). They had $1.9M working capital deficiency as of Feb 28 2023 as per Rights offering doc.   ...more  
255
Comment by C10H12N2on Mar 30, 2023 7:11pm

RE:RE:RE:RE:A Message To Board Director - Dr. Mark Williams, PhD, MBA

Dunno. I report. You decide. What I'd surmise at first glance is Williams likely held back what he'd consider his best repurposed drug candidate for himself. Of all the repurposed drug ...more  
93
Discussion
Comment by Whalewatcher1on Mar 30, 2023 7:09pm

RE:RE:Upcoming Work

And don't forget these guys are more interested in promoting the stock by using cash on marketing and not drug development. Someone should tell them that marketing comes after approval hahah
59
Discussion
Comment by Whalewatcher1on Mar 30, 2023 6:31pm

RE:RE:RE:A Message To Board Director - Dr. Mark Williams, PhD, MBA

The so called Dr Williams is doing the same so called "repurposing" pitch at marvel bioscience. Looks like they also are alimony out of cash. Who's going to be holding the bag in these ...more  
74
Discussion
Comment by Whalewatcher1on Mar 30, 2023 6:24pm

RE:Upcoming Work

So how will these clinical trials be finding when the company has over $2M in payables and no Cdh based on financial statements. They are doing a rights offering that likely won't even cover the ...more  
75
Discussion
Post by SkywalkerofLukeon Mar 30, 2023 2:14pm

Upcoming Work

AGN.c AGNPF is currently undergoing clinical studies and the results could be a major catalyst if they’re successful. Some of their upcoming work includes - Have a 180 patient, 90-day Phase 2b ...more  
192
Discussion
Comment by C10H12N2on Mar 29, 2023 2:48am

RE:RE:A Message To Board Director - Dr. Mark Williams, PhD, MBA

Further clarification for the slow one here. Maybe this will send him back to whatever cave he crawled out of these days? However, he'll likely have a so-called opinion about something else he ...more  
71
Discussion
Comment by C10H12N2on Mar 29, 2023 2:40am

RE:RE:A Message To Board Director - Dr. Mark Williams, PhD, MBA

Wrong as usual but don't let that stop you from trolling all over again. Also, who cares about arch? if anyone reads that board they'll see where your hype and river dances is complete ...more  
56
Discussion
Prev 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 ... Next
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities